Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Saved in:
| Title: | Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. |
|---|---|
| Authors: | Le Teuff G; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France. Gwenael.LETEUFF@gustaveroussy.fr., Cozic N; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Boyer JC; Service de Biochimie et Biologie Moléculaire, CHU Carémeau, Nîmes, France., Boige V; Department of cancer medicine, Gustave-Roussy Cancer Campus, Paris-Saclay and Paris-Sud Universities, Villejuif, France.; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France., Diasio RB; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Cancer Center, Rochester, MN, USA., Taieb J; Université Paris-Cité, SIRIC CARPEM, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP-HP, Paris, France., Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Palles C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Schwab M; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University of Tuebingen, Tuebingen, Germany.; Cluster of Excellence IFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, 72074, Tübingen, Germany., Deenen M; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Largiadèr CR; Department of Clinical Chemistry, Bern University Hospital, University of Bern, Inselspital, Bern, Switzerland., Marinaki A; Purine Research Laboratory, St Thomas' Hospital, London, UK., Jennings BA; Norwich Medical School, University of East Anglia, Norwich, UK., Wettergren Y; Sahlgrenska University Hospital, Goteborg, Sweden., Di Paolo A; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Gross E; LMU Munich, University Hospital, Campus Grosshadern, Munich, Germany., Budai B; National Institute of Oncology, Budapest, Hungary., Ackland SP; College of Heath, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia., van Kuilenburg ABP; Amsterdam UMC, location University of Amsterdam, Laboratory Genetic Metabolic Diseases, Meibergdreef 9, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Imaging and biomarkers, Amsterdam, The Netherlands., McLeod HL; Intermountain Precision Genomics, Intermountain Healthcare, St George, UT, USA., Milano G; Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France., Thomas F; Institut Claudius Regaud, IUCT-Oncopôle and CRCT, University of Toulouse, Inserm, Toulouse, France., Loriot MA; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France.; Hôpital Européen Georges Pompidou, Hôpitaux Universitaires Paris Ouest, Paris, France., Kerr D; Nuffield Division of Clinical and Laboratory Sciences and University of Oxford, Oxford, UK., Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Laurent-Puig P; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France.; Hôpital Européen Georges Pompidou, Hôpitaux Universitaires Paris Ouest, Paris, France., Shi Q; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Pignon JP; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Etienne-Grimaldi MC; Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France. |
| Corporate Authors: | FUSAFE collaborative group |
| Source: | British journal of cancer [Br J Cancer] 2024 Mar; Vol. 130 (5), pp. 808-818. Date of Electronic Publication: 2024 Jan 15. |
| Publication Type: | Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
